A pilot single-centre double-blind randomised controlled trial of the effect of centhaquine on stroke volume in the treatment of vasodilatory hypotension in adults admitted to the intensive care unit

Phase 2

Recruiting

• Conditions: hypotension; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12624000384550
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-04-03
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

Adults aged equal to or greater than 18 years
Vasopressor dependent hypotension (vasopressor therapy to maintain a mean arterial pressure greater than 65 mmHg)
Cardiac index > 2.3 litres per minute per meters squared or central venous oxygen saturation > 70 percent
Central venous access and an arterial line present
Expected to require vasopressor support for at least 24 hours
Informed consent provided by the patient or medical treatment decision maker

Exclusion Criteria

Cardiac surgery patients
Suspected cardiogenic shock
Greater than 24 hours continuous vasoactive therapy prior to enrolment
Chronic haemodialysis or peritoneal dialysis
Expected survival less than 24 hours
Suspected or confirmed pregnancy
Previously enrolled into the this trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Stroke volume[milliliter as measured by pulse-contour analysis Recorded every hour over the six hours after initiation of the study infusion as recorded in the patient's medical record]